PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING COLORECTAL CANCER COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS, AND METHOD FOR PREPARING SAME
A pharmaceutical composition for preventing and treating colorectal cancer comprising K-ras-specific activated T cells, according to the present invention, is an antigen composition, in which K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptides are divided into a total of 12 epitopes (n=1 to 12, wherein the last epitope (n=12) is 23 amino acids) in units of 30 consecutive amino acids in the amino acid sequence of K-ras, and are designed to overlap 15 amino acid sequences between the epitopes, resulting in advantages of being more effective in recognizing and killing colorectal cancer in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Therefore, when the pharmaceutical composition for preventing and treating colorectal cancer comprising K-ras-specific activated T cells, according to the present invention, is used, there are advantages of being able to effectively prevent and treat colorectal cancer, particularly, colorectal adenocarcinoma, in which K-ras as well as K-ras mutants are detected..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 06. Juli Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEE WANG JUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 |
|---|
| Patentnummer: |
WO2023128378 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017656931 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017656931 | ||
| 003 | DE-627 | ||
| 005 | 20230811085338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230721s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017656931 | ||
| 035 | |a (EPA)WO2023128378 | ||
| 035 | |a (EPA)86999550 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEE WANG JUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING COLORECTAL CANCER COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS, AND METHOD FOR PREPARING SAME |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 | ||
| 520 | |a A pharmaceutical composition for preventing and treating colorectal cancer comprising K-ras-specific activated T cells, according to the present invention, is an antigen composition, in which K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptides are divided into a total of 12 epitopes (n=1 to 12, wherein the last epitope (n=12) is 23 amino acids) in units of 30 consecutive amino acids in the amino acid sequence of K-ras, and are designed to overlap 15 amino acid sequences between the epitopes, resulting in advantages of being more effective in recognizing and killing colorectal cancer in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Therefore, when the pharmaceutical composition for preventing and treating colorectal cancer comprising K-ras-specific activated T cells, according to the present invention, is used, there are advantages of being able to effectively prevent and treat colorectal cancer, particularly, colorectal adenocarcinoma, in which K-ras as well as K-ras mutants are detected. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MOON HYOUN JONG |4 aut | |
| 700 | 0 | |a LIM SUN KI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 06. Juli |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86999550/publication/WO2023128378A1?q=WO2023128378 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 06 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 07 | ||